GLPG1690 – 25 mg

Brand:
Cayman
CAS:
1628260-79-6
Storage:
-20
UN-No:
Non-Hazardous - /

GLP1690 is a potent inhibitor of autotaxin (Ki = 15 nM).{36941} It inhibits the production of lysophosphatidic acid (LPA) in mouse, rat, and human plasma (IC50s = 418, 542, and 242 nM, respectively). GLPG1690 (30 mg/kg) reduces extracellular matrix deposition in the lung as well as LPA 18:2 levels in bronchoalveolar lavage fluid in a mouse model of pulmonary fibrosis induced by bleomycin (Item No. 13877).  

 

Available on backorder

SKU: 25498 - 25 mg Category:

Description

A potent autotaxin inhibitor (Ki = 15 nM); inhibits production of LPA in mouse, rat, and human plasma (IC50s = 418, 542, and 242 nM, respectively); reduces extracellular matrix deposition in the lung as well as LPA 18:2 levels in bronchoalveolar lavage fluid in a mouse model of bleomycin-induced pulmonary fibrosis at 30 mg/kg


Formal name: 2-[[2-ethyl-6-[4-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]-1-piperazinyl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)-5-thiazolecarbonitrile

Synonyms: 

Molecular weight: 588.7

CAS: 1628260-79-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Immunology & Inflammation|Pulmonary Diseases